期刊
MOLECULAR AND CELLULAR ENDOCRINOLOGY
卷 297, 期 1-2, 页码 137-140出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.mce.2008.11.018
关键词
GLP-1 analogue; Hypoglycaemia; Body weight; Systolic blood pressure
资金
- Novo Nordisk A/S, Bagsvaerd, Denmark
Liraglutide, a human glucagon-like peptide 1 (GLP-1) analogue with high homology to native GLP-1, has structural modifications sufficient to amend pharmacokinetics for once-daily administration without compromising biological activity. Data from large, controlled, clinical Studies have confirmed the therapeutic profile of liraglutide, with robust reductions in HbA(1c), low risk of hypoglycaemia and clinically relevant reductions in body weight and systolic blood pressure. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据